MAPK8 and plasma cell myeloma: Combined treatment with bortezomib and WT161 in MM.1S cells elicits greater accumulation of polyubiquitinated proteins and activation of stress-activated protein kinase JNK compared to either agent alone.[48] Furthermore, this combination demonstrates potent anti-myeloma activity in human MM xenograft models.